Hatim Sabaawy, MD, PhD, MS

Professional Titles

• Associate Director of Translational Research
• Professor of Medicine
• Director of Personalized Medicine, Division of Medical Oncology
• Margaret and Hugh Stapp Endowed Chair for Cancer Research

Publications

• Vaddi P, Strange A, Liu L, Davis S, Yusuff S, Flaherty K, Jara K, Kramer J, Archer C, Pine SR, Wang W, Nakamura T, Sabaawy HE. An evolutionary-conserved molecular signature of cell senescence. Systems Approaches to Cancer Biology, 2025. sacbmeeting.org/public/PosterPresentationAbstracts2025.pdf, page 25.
• Strange A, Liu L, Vaddi P, Lee S, Gao B, Menon Ravindran D, Merrick D, Aisner S, van Bokhoven A, Patil T, Camidge DR, Pine SR, and Sabaawy HE. High plex single cell spatial signatures of lung cancer resistance to therapy. Systems Approaches to Cancer Biology, 2025. sacbmeeting.org/public/PosterPresentationAbstracts2025.pdf, page 40.
• Liu L, Davis S, Yusuff S, Strange A, Zhuang Y, Vaddi P, Flaherty K, Jara K, Kramer J, Archer C, Lee S, Gao B, van Bokhoven A, Wang W, Pine SR, Nakamura T, Sabaawy HE. Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer. BioRxiv 2024. Doi: 10.1101/2024.12.28.630560. ID: 630560.
• Pine SR, Watson AS, Patil T, Schenk EL, Merrick D, Camidge DR, and Sabaawy HS. Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing. Journal of Clinical Oncology, Volume 42, Number 16_suppl. https://doi.org/10.1200/JCO.2024.42.16_suppl.e20521.
• Liu L, Strange S, Lee S, Gao B, Merrick D, Patil T, DeGregori J, Camidge DR, Pine SR, and Sabaawy HE. Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens. Cancer Research, 2024, Volume 84, Supplement 6: 6496. https://doi.org/10.1158/1538-7445.AM2024-6496.
• Pine SR, Watson AS, Patil T, Schenk EL, Merrick D, Camidge DR, and Sabaawy HS. Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing. Journal of Clinical Oncology, Volume 42, Number 16_suppl. https://doi.org/10.1200/JCO.2024.42.16_suppl.e20521.
• Liu L, Strange S, Lee S, Gao B, Merrick D, Patil T, DeGregori J, Camidge DR, Pine SR, and Sabaawy HE. Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens. Cancer Research, 2024, Volume 84, Supplement 6: 6496. https://doi.org/10.1158/1538-7445.AM2024-6496
• Liu L, Davis S, Yusuff S, Strange A, Zhuang Y, Vaddi P, Flaherty K, Jara K, Kramer J, Archer C, Lee S, Gao B, van Bokhoven A, Wang W, Pine SR, Nakamura T, Sabaawy HE. Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer. BioRxiv 2024. Doi: 10.1101/2024.12.28.630560. ID: 630560.
• Sabaawy HE, Broggini M, Gupta SK. Patient-derived tumor models for drug development. Front Oncol. 2023;13:1243534. PubMed PMID: 37483498
• Zhong H, Lu W, Tang Y, Wiel C, Wei Y, Cao J, Riedlinger G, Papagiannakopoulos T, Guo JY, Bergo MO, Kang Y, Ganesan S, Sabaawy HE, Pine SR. SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity. Oncogene. 2023 Jun;42(27):2183-2194. PubMed PMID: 37258742
• Laureano AS, Flaherty K, Hinman AM, Jadali A, Nakamura T, Higashijima SI, Sabaawy HE, Kwan KY. shox2 is required for vestibular statoacoustic neuron development. Biol Open. 2022 Dec 15;11(12). PubMed PMID: 36594417
• Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 Sep 6;21(9):1381-1392. PubMed PMID: 35732569
• Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer EA, Jang TL, Ghodoussipour S, Saraiya B, Mayer T, Sabaawy HE, Yuh B, Byun SS, Kim WJ, Horie S. Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate Int. 2022 Jun;10(2):75-79. PubMed PMID: 35510081
• Al-Zubaydi F, Gao D, Kakkar D, Li S, Holloway J, Szekely Z, Chan N, Kumar S, Sabaawy HE, Love S, Sinko PJ. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy. Drug Deliv Transl Res. 2022 Jan;12(1):240-256. PubMed PMID: 33590464

Professional Memberships

• American Society of Clinical Oncology (ASCO), Full member
• American Association of Cancer Research (AACR), Full member

Practice Locations

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

Hospital Affiliation

• University of Colorado Hospital